Skip to main content
SpringerLink
Log in

Drug interactions with oral anticoagulants in German nursing home residents: comparison between vitamin K antagonists and non-vitamin K antagonist oral anticoagulants based on two nested case–control studies

  • Original Paper
  • Published:
Clinical Research in Cardiology Aims and scope Submit manuscript

Abstract

Background

Vitamin K antagonists (VKAs) are susceptible to drug–drug interactions. Non-VKA oral anticoagulants (NOACs) have a decreased sensitivity to pharmacokinetic interactions and might be therefore considered superior in patients treated with multiple drugs. The objective of this study was to compare the risk of serious bleeding associated with interacting drugs in German nursing home residents treated with VKA or NOAC.

Methods

Using claims data of new nursing home residents aged ≥ 65 years (2010–2014) we conducted separate nested case–control analyses within two cohorts of patients treated with VKA or NOAC, respectively. Cases were defined as patients hospitalized for serious bleeding. For each case, up to 20 controls were selected by risk-set sampling. Conditional logistic regression was used to obtain confounder-adjusted odds ratios (aORs) and 95% confidence intervals (CI) for the risk of bleeding associated with VKA or NOAC use and interacting drugs compared with the use of the respective oral anticoagulant alone.

Results

Among 127,227 new nursing home residents, 16,804 patients received oral anticoagulation. Based on 372 cases and 7281 matched controls, the highest risk of bleeding in VKA users was observed for the concomitant use of antibiotics (aOR 3.00; CI 2.11–4.27) vs. VKA use alone, followed by non-steroidal anti-inflammatory drugs (1.66; 1.13–2.43). Among 243 NOAC cases and 4776 matched controls, elevated risks for bleeding were observed for the use of heparins (2.05; 1.25–3.36) and platelet inhibitors (1.92; 1.36–2.72).

Conclusions

Concomitant medication needs to be prescribed cautiously and monitored closely in nursing home residents treated with oral anticoagulants.

Graphic Abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Barnes GD, Lucas E, Alexander GC, Goldberger ZD (2015) National trends in ambulatory oral anticoagulant use. Am J Med 128:1300–1305.e2. https://doi.org/10.1016/j.amjmed.2015.05.044

    Article  PubMed  PubMed Central  Google Scholar 

  2. Loo SY, Dell’Aniello S, Huiart L, Renoux C (2017) Trends in the prescription of novel oral anticoagulants in UK primary care. Br J Clin Pharmacol 83:2096–2106. https://doi.org/10.1111/bcp.13299

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Gadsbøll K, Staerk L, Fosbøl EL et al (2017) Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark. Eur Heart J 38:899–906. https://doi.org/10.1093/eurheartj/ehw658

    Article  CAS  PubMed  Google Scholar 

  4. Hein L, Wille H (2018) Antithrombotika und Antihämorrhagika. Arzneiverordnungs-report 2018. Springer, Berlin, pp 401–421

    Chapter  Google Scholar 

  5. Shehab N, Lovegrove MC, Geller AI et al (2016) US emergency department visits for outpatient adverse drug events, 2013–2014. JAMA 316:2115. https://doi.org/10.1001/jama.2016.16201

    Article  PubMed  PubMed Central  Google Scholar 

  6. Vazquez SR (2018) Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions. Blood 132:2230–2239. https://doi.org/10.1182/blood-2018-06-848747

    Article  CAS  PubMed  Google Scholar 

  7. Pharma GmbH MEDA, Co KG (2018) Marcumar. Summary of products characteristics. Fachinfo-Service, Frankfurt

    Google Scholar 

  8. Squibb Bristol-Myers (2017) Coumadin. Summary of products characteristics. Fachinfo-Service, Frankfurt

    Google Scholar 

  9. Snyder BD, Polasek TM, Doogue MP (2012) Drug interactions: principles and practice. Aust Prescr. https://doi.org/10.18773/austprescr.2012.037

    Article  Google Scholar 

  10. Gelosa P, Castiglioni L, Tenconi M et al (2018) Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs). Pharmacol Res 135:60–79. https://doi.org/10.1016/j.phrs.2018.07.016

    Article  CAS  PubMed  Google Scholar 

  11. Zotz RB, Weißbach L (2017) Monitoring of NOAC. Med Klin Intensivmed Notfmed 112:92–98. https://doi.org/10.1007/s00063-016-0249-6

    Article  CAS  PubMed  Google Scholar 

  12. Stöllberger C (2017) Drug interactions with new oral anticoagulants in elderly patients. Expert Rev Clin Pharmacol. https://doi.org/10.1080/17512433.2017.1370369

    Article  PubMed  Google Scholar 

  13. Hohnloser SH, Basic E, Nabauer M (2019) Uptake in antithrombotic treatment and its association with stroke incidence in atrial fibrillation: insights from a large German claims database. Clin Res Cardiol. https://doi.org/10.1007/s00392-019-01437-7

    Article  PubMed  Google Scholar 

  14. Reardon G, Pandya N, Nutescu EA et al (2013) Incidence of venous thromboembolism in nursing home residents. J Am Med Dir Assoc 14:578–584. https://doi.org/10.1016/j.jamda.2013.02.003

    Article  PubMed  Google Scholar 

  15. Sinnaeve PR, Brueckmann M, Clemens A et al (2012) Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation. J Intern Med 271:15–24. https://doi.org/10.1111/j.1365-2796.2011.02464.x

    Article  CAS  PubMed  Google Scholar 

  16. Jobski K, Hoffmann F, Herget-Rosenthal S, Dörks M (2018) Use of oral anticoagulants in German nursing home residents: drug use patterns and predictors for treatment choice. Br J Clin Pharmacol 84:590–601. https://doi.org/10.1111/bcp.13474

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Dörks M, Herget-Rosenthal S, Schmiemann G, Hoffmann F (2016) Polypharmacy and renal failure in nursing home residents: results of the inappropriate Medication in Patients with Renal Insufficiency in Nursing Homes (IMREN) Study. Drugs Aging 33:45–51. https://doi.org/10.1007/s40266-015-0333-2

    Article  CAS  PubMed  Google Scholar 

  18. Palareti G, Cosmi B (2009) Bleeding with anticoagulation therapy—who is at risk, and how best to identify such patients. Thromb Haemost. https://doi.org/10.1160/TH08-11-0730

    Article  PubMed  Google Scholar 

  19. Wacholder S, Silverman DT, McLaughlin JK, Mandel JS (1992) Selection of controls in case-control studies. III. Design options. Am J Epidemiol 135:1042–1050

    Article  CAS  PubMed  Google Scholar 

  20. Jobski K, Behr S, Garbe E (2011) Drug interactions with phenprocoumon and the risk of serious haemorrhage: a nested case–control study in a large population-based German database. Eur J Clin Pharmacol 67:941–951. https://doi.org/10.1007/s00228-011-1031-6

    Article  PubMed  Google Scholar 

  21. Abbas S, Ihle P, Harder S, Schubert I (2014) Risk of bleeding and antibiotic use in patients receiving continuous phenprocoumon therapy. Thromb Haemost 111:912–922. https://doi.org/10.1160/TH13-09-0723

    Article  CAS  PubMed  Google Scholar 

  22. Chang SH, Chou IJ, Yeh YH et al (2017) Association between use of non–vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. JAMA J Am Med Assoc 318:1250–1259. https://doi.org/10.1001/jama.2017.13883

    Article  CAS  Google Scholar 

  23. Büscher A, Wingenfeld K, Schaeffer D (2011) Determining eligibility for long-term care-lessons from Germany. Int J Integr Care 11:e019. https://doi.org/10.5334/ijic.584

    Article  PubMed  PubMed Central  Google Scholar 

  24. Langan SM, Schmidt SA, Wing K et al (2018) The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ 363:k3532. https://doi.org/10.1136/bmj.k3532

    Article  PubMed  PubMed Central  Google Scholar 

  25. Ihle P, Krueger K, Schubert I et al (2019) Comparison of different strategies to measure medication adherence via claims data in patients with chronic heart failure. Clin Pharmacol Ther. https://doi.org/10.1002/cpt.1378

    Article  PubMed  PubMed Central  Google Scholar 

  26. Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation.[Erratum appears in N Engl J Med. 2010 Nov 4;363(19):1877]. N Engl J Med. https://doi.org/10.1056/NEJMoa0905561

    Article  PubMed  Google Scholar 

  27. Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891. https://doi.org/10.1056/NEJMoa1009638

    Article  CAS  PubMed  Google Scholar 

  28. Granger CB, Alexander JH, McMurray JJV et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992. https://doi.org/10.1056/NEJMoa1107039

    Article  CAS  PubMed  Google Scholar 

  29. Agnelli G, Buller HR, Cohen A et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369:799–808. https://doi.org/10.1056/NEJMoa1302507

    Article  CAS  PubMed  Google Scholar 

  30. Investigators EINSTEIN, Bauersachs R, Berkowitz SD et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499–2510. https://doi.org/10.1056/NEJMoa1007903

    Article  Google Scholar 

  31. EINSTEIN–PE Investigators, Büller HR, Prins MH et al (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:1287–1297. https://doi.org/10.1056/nejmoa1113572

    Article  Google Scholar 

  32. Sjögren V, Byström B, Renlund H et al (2017) Non-Vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: a retrospective register study. PLoS One. https://doi.org/10.1371/journal.pone.0181000

    Article  PubMed  PubMed Central  Google Scholar 

  33. Yao X, Abraham NS, Sangaralingham LR et al (2016) Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. https://doi.org/10.1161/JAHA.116.003725

    Article  PubMed  PubMed Central  Google Scholar 

  34. Larsen TB, Skjøth F, Nielsen PB et al (2016) Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. https://doi.org/10.1136/bmj.i3189

    Article  PubMed  PubMed Central  Google Scholar 

  35. Lip GYH, Keshishian A, Kamble S et al (2016) Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin: a propensity score matched analysis. Thromb Haemost. https://doi.org/10.1160/TH16-05-0403

    Article  PubMed  Google Scholar 

  36. Ujeyl M, Köster I, Wille H et al (2018) Comparative risks of bleeding, ischemic stroke and mortality with direct oral anticoagulants versus phenprocoumon in patients with atrial fibrillation. Eur J Clin Pharmacol. https://doi.org/10.1007/s00228-018-2504-7

    Article  PubMed  Google Scholar 

  37. Hohnloser SH, Basic E, Nabauer M (2017) Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study. Clin Res Cardiol. https://doi.org/10.1007/s00392-017-1098-x

    Article  PubMed  Google Scholar 

  38. Takach Lapner S, Cohen N, Kearon C (2014) Influence of sex on risk of bleeding in anticoagulated patients: a systematic review and meta-analysis. J Thromb Haemost. https://doi.org/10.1111/jth.12529

    Article  PubMed  Google Scholar 

  39. Floyd CN, Ferro A (2017) Indications for anticoagulant and antiplatelet combined therapy. BMJ. https://doi.org/10.1136/bmj.j3782

    Article  PubMed  Google Scholar 

  40. Hansen ML, Sørensen R, Clausen MT et al (2010) Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. https://doi.org/10.1001/archinternmed.2010.271

    Article  PubMed  Google Scholar 

  41. Oldgren J, Wallentin L, Alexander JH et al (2013) New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J 34:1670–1680. https://doi.org/10.1093/eurheartj/eht049

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Duerschmied D, Brachmann J, Darius H et al (2018) Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials? Clin Res Cardiol. https://doi.org/10.1007/s00392-018-1242-2

    Article  PubMed  PubMed Central  Google Scholar 

  43. Bjarnason I, Scarpignato C, Holmgren E et al (2018) Mechanisms of damage to the gastrointestinal tract from nonsteroidal anti-inflammatory drugs. Gastroenterology 154:500–514. https://doi.org/10.1053/j.gastro.2017.10.049

    Article  CAS  PubMed  Google Scholar 

  44. Ray WA, Chung CP, Murray KT et al (2018) Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA 320:2221. https://doi.org/10.1001/jama.2018.17242

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Henriksen DP, Stage TB, Hansen MR et al (2015) The potential drug–drug interaction between proton pump inhibitors and warfarin. Pharmacoepidemiol Drug Saf. https://doi.org/10.1002/pds.3881

    Article  PubMed  Google Scholar 

  46. Jobski K, Schmedt N, Kollhorst B et al (2017) Characteristics and drug use patterns of older antidepressant initiators in Germany. Eur J Clin Pharmacol 73:105–113. https://doi.org/10.1007/s00228-016-2145-7

    Article  CAS  PubMed  Google Scholar 

  47. Bouillon K, Bertrand M, Boudali L et al (2016) Short-term risk of bleeding during heparin bridging at initiation of vitamin K antagonist therapy in more than 90 000 patients with nonvalvular atrial fibrillation managed in outpatient care. J Am Heart Assoc 1:1. https://doi.org/10.1161/JAHA.116.004065

    Article  Google Scholar 

  48. Siegal D, Yudin J, Kaatz S et al (2012) Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.112.105221

    Article  PubMed  Google Scholar 

  49. Bauersachs R, Agnelli G, Gitt AK et al (2017) The role of heparin lead-in in the real-world management of acute venous thromboembolism: the PREFER in VTE registry. Thromb Res 157:181–188. https://doi.org/10.1016/j.thromres.2017.07.029

    Article  CAS  PubMed  Google Scholar 

  50. Holm J, Lindh JD, Andersson ML, Mannheimer B (2017) The effect of amiodarone on warfarin anticoagulation: a register-based nationwide cohort study involving the Swedish population. J Thromb Haemost. https://doi.org/10.1111/jth.13614

    Article  PubMed  Google Scholar 

  51. Lochner S, Kirch W, Schindler C (2012) Managing hypertension among nursing-home residents and community-dwelling elderly in Germany: a comparative pharmacoepidemiological study. Eur J Clin Pharmacol. https://doi.org/10.1007/s00228-011-1195-0

    Article  PubMed  Google Scholar 

  52. Hughes CM, Goldie R (2009) “I just take what i am given”: adherence and resident involvement in decision making on medicines in nursing homes for older people: a qualitative survey. Drugs Aging. https://doi.org/10.2165/00002512-200926060-00007

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank the DAK-Gesundheit for providing the data for this study.

Author information

Authors and Affiliations

  1. Department of Health Services Research, Carl von Ossietzky University Oldenburg, Ammerländer Heerstr. 114-118, 26129, Oldenburg, Germany

    Kathrin Jobski, Falk Hoffmann & Michael Dörks

  2. Department of Medicine, Rotes Kreuz Hospital, Bremen, Germany

    Stefan Herget-Rosenthal

Authors
  1. Kathrin Jobski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Falk Hoffmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stefan Herget-Rosenthal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Dörks
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kathrin Jobski.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 66 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jobski, K., Hoffmann, F., Herget-Rosenthal, S. et al. Drug interactions with oral anticoagulants in German nursing home residents: comparison between vitamin K antagonists and non-vitamin K antagonist oral anticoagulants based on two nested case–control studies. Clin Res Cardiol 109, 465–475 (2020). https://doi.org/10.1007/s00392-019-01526-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-019-01526-7

Keywords

Search

Navigation